Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 8/20 | 0.85 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.85 |
| ▸ | PPARA | Q07869 | 1/20 | 0.79 |
| ▸ | MEN1 | O00255 | 13/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 13/20 | 0.76 |
| ▸ | MAPT | P10636 | 7/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.76 |
| ▸ | APEX1 | P27695 | 4/20 | 0.76 |
| ▸ | RECQL | P46063 | 3/20 | 0.76 |
| ▸ | HPGD | P15428 | 2/20 | 0.76 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.76 |
| ▸ | PKM | P14618 | 7/20 | 0.74 |
| ▸ | BLM | P54132 | 3/20 | 0.74 |
| ▸ | CTDSP1 | Q9GZU7 | 3/20 | 0.74 |
| ▸ | SAE1 | Q9UBE0 | 2/20 | 0.74 |
| ▸ | UBA2 | Q9UBT2 | 2/20 | 0.74 |
| ▸ | CASP3 | P42574 | 1/20 | 0.68 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14426577 | 1.00 | POLB (0.85) | POLBSMN1; SMN2PPARAMEN1KMT2A | |
| SCHEMBL14426580 | 0.86 | KMT2A (1.00) | POLBSMN1; SMN2PPARAMEN1KMT2A | |
| SCHEMBL14426593 | 0.85 | KMT2A (1.00) | POLBSMN1; SMN2PPARAMEN1KMT2A | |
| SCHEMBL46575 | 0.81 | ITGB2 (0.69) | POLBSMN1; SMN2PPARAMEN1KMT2A | |
| SCHEMBL14292055 | 0.78 | KMT2A (0.84) | POLBSMN1; SMN2PPARAMEN1KMT2A | |
| SCHEMBL14291479 | 0.74 | KMT2A (0.80) | POLBSMN1; SMN2PPARAMEN1KMT2A | |
| SCHEMBL29901211 | 0.73 | MEN1 (0.65) | POLBSMN1; SMN2PPARAMEN1KMT2A | |
| SCHEMBL46257 | 0.72 | ITGB2 (1.00) | POLBSMN1; SMN2PPARAMEN1KMT2A | |
| SCHEMBL14426456 | 0.70 | LCK (1.00) | POLBSMN1; SMN2PPARAMEN1KMT2A | |
| SCHEMBL14507111 | 0.70 | MEN1 (0.69) | POLBSMN1; SMN2PPARAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312367-A1 | OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2025-10-09 | — | — | US | disclosed |
| EP-4522628-A2 | OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF | Adarx Pharmaceuticals, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023220737-A2 | OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-4269437-A1 | PD-1 BINDING MOLECULE AND APPLICATION THEREOF | Zhejiang Nanomab Technology Center Co. Ltd. (CN) | 2023-11-01 | — | — | EP | disclosed |
| CN-116829718-A | PD-1 binding molecules and uses thereof | 浙江纳米抗体技术中心有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2022143552-A1 | PD-1 BINDING MOLECULE AND APPLICATION THEREOF | 浙江纳米抗体技术中心有限公司 | 2022-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312367-A1 | OLIGONUCLEOTIDES HAVING A SYNTHETIC BACKBONE AND SYNTHESIS THEREOF | POLRMT, TARDBP, NSUN2 | POLB 20/4885SMN1; SMN2 7/4885PPARA 3137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.